Analysts Set Akero Therapeutics, Inc. (NASDAQ:AKRO) PT at $43.20

Akero Therapeutics, Inc. (NASDAQ:AKRO) has been given an average rating of “Moderate Buy” by the seven analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $43.20.

Separately, HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Akero Therapeutics in a research note on Tuesday, September 17th.

Insider Activity at Akero Therapeutics

In other Akero Therapeutics news, CFO William Richard White sold 139,083 shares of the stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $26.98, for a total value of $3,752,459.34. Following the completion of the transaction, the chief financial officer now owns 41,791 shares in the company, valued at approximately $1,127,521.18. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO William Richard White sold 139,083 shares of the business’s stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $26.98, for a total transaction of $3,752,459.34. Following the sale, the chief financial officer now owns 41,791 shares in the company, valued at approximately $1,127,521.18. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Andrew Cheng sold 1,738 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $26.18, for a total transaction of $45,500.84. Following the completion of the transaction, the chief executive officer now owns 605,417 shares of the company’s stock, valued at approximately $15,849,817.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 393,398 shares of company stock worth $11,192,629 over the last ninety days. 7.94% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rheos Capital Works Inc. grew its stake in shares of Akero Therapeutics by 27.8% in the third quarter. Rheos Capital Works Inc. now owns 276,000 shares of the company’s stock worth $7,918,000 after acquiring an additional 60,000 shares during the last quarter. Creative Planning purchased a new stake in Akero Therapeutics during the 3rd quarter valued at about $371,000. Handelsbanken Fonder AB increased its stake in Akero Therapeutics by 12.4% during the 3rd quarter. Handelsbanken Fonder AB now owns 20,000 shares of the company’s stock valued at $574,000 after purchasing an additional 2,200 shares in the last quarter. Perceptive Advisors LLC raised its holdings in Akero Therapeutics by 8.1% in the second quarter. Perceptive Advisors LLC now owns 1,499,897 shares of the company’s stock worth $35,188,000 after buying an additional 112,426 shares during the last quarter. Finally, Long Focus Capital Management LLC lifted its stake in shares of Akero Therapeutics by 119.0% in the second quarter. Long Focus Capital Management LLC now owns 719,604 shares of the company’s stock worth $16,882,000 after buying an additional 391,000 shares in the last quarter.

Akero Therapeutics Price Performance

Shares of Akero Therapeutics stock opened at $31.23 on Friday. The company’s fifty day simple moving average is $27.36 and its two-hundred day simple moving average is $24.24. Akero Therapeutics has a 12-month low of $11.25 and a 12-month high of $37.00. The firm has a market cap of $2.16 billion, a PE ratio of -9.76 and a beta of -0.25. The company has a quick ratio of 24.89, a current ratio of 24.89 and a debt-to-equity ratio of 0.04.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Friday, August 9th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. As a group, equities analysts expect that Akero Therapeutics will post -3.64 EPS for the current year.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.